Stockscreener 앱 받기
3.84
1.05%
0.04
시간 외 거래:
3.98
0.14
+3.65%
전일 마감가:
$3.80
열려 있는:
$3.77
하루 거래량:
554.22K
Relative Volume:
0.18
시가총액:
$405.45M
수익:
$234.04M
순이익/손실:
$-323.92M
주가수익비율:
-0.8477
EPS:
-4.53
순현금흐름:
$-223.46M
1주 성능:
-10.90%
1개월 성능:
-27.27%
6개월 성능:
+27.57%
1년 성능:
-46.89%
1일 변동 폭
$3.76
$3.88
1주일 범위
$3.64
$4.30
52주 변동 폭
$2.30
$9.745
Revance Therapeutics Inc Stock (RVNC) Company Profile
명칭
Revance Therapeutics Inc
전화
(615) 724-7755
주소
1222 DEMONBREUN STREET, NASHVILLE, CA
RVNC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| RVNC | 3.84 | 405.45M | 234.04M | -323.92M | -223.46M | -4.53 |
| VRTX | 450.37 | 115.10B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 596.74 | 35.07B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.80 | 32.20B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.23 | 25.09B | 3.30B | -501.07M | 1.03B | 11.54 |
Revance Therapeutics Inc Stock (RVNC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-08-16 | 업그레이드 | Exane BNP Paribas | Underperform → Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-09-22 | 개시 | Goldman | Buy |
| 2021-10-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-10-15 | 재확인 | Needham | Buy |
| 2020-08-11 | 재개 | Mizuho | Buy |
| 2020-03-23 | 다운그레이드 | Goldman | Buy → Neutral |
| 2019-12-02 | 개시 | Goldman | Buy |
| 2019-10-30 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2019-06-11 | 개시 | Barclays | Overweight |
| 2019-02-15 | 개시 | Wells Fargo | Market Perform |
| 2019-02-14 | 개시 | H.C. Wainwright | Buy |
| 2019-01-29 | 개시 | Stifel | Buy |
| 2018-11-16 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2018-09-17 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-04-20 | 재확인 | Mizuho | Buy |
| 2018-03-27 | 개시 | Needham | Buy |
| 2018-03-05 | 개시 | Goldman | Buy |
| 2018-01-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2017-12-06 | 개시 | Guggenheim | Buy |
| 2017-12-06 | 재확인 | Mizuho | Buy |
| 2017-11-27 | 개시 | Barclays | Overweight |
| 2017-11-17 | 개시 | Mizuho | Buy |
| 2017-08-22 | 개시 | JMP Securities | Mkt Outperform |
모두보기
Revance Therapeutics Inc 주식(RVNC)의 최신 뉴스
Revance Therapeutics sinks amid `going concern' disclosure - MSN
Alpine Associates Management Inc. Takes Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - MarketBeat
Revance and Crown extend merger offer date to November 26 - Investing.com India
Revance and Crown extend merger offer date to November 26 By Investing.com - Investing.com Nigeria
Revance Therapeutics gains as Crown Labs further extends tender offer - MSN
LMR Partners LLP Acquires New Shares in Revance Therapeutics, Inc. (NASDAQ:RVNC) - MarketBeat
Revance Therapeutics (NASDAQ:RVNC) Now Covered by Analysts at StockNews.com - MarketBeat
Neurotoxin Market Overall Study Report 2024-2032 | Revance - openPR
Revance, Crown Labs Again Extend Tender Offer Start Deadline - MarketWatch
Revance Therapeutics jumps after Crown Laboratories tender offer extended again - MSN
Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives $9.66 Consensus Target Price from Analysts - MarketBeat
StockNews.com Begins Coverage on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ROIC, PWUP, RVNC on Behalf of Shareholders - GlobeNewswire Inc.
Where are the Opportunities in (RVNC) - Stock Traders Daily
Revance Therapeutics (NASDAQ:RVNC) Given Hold Rating at Needham & Company LLC - MarketBeat
Revance Therapeutics' (RVNC) Neutral Rating Reaffirmed at HC Wainwright - MarketBeat
Revance Therapeutics, Inc. (RVNC) Reports Q3 Loss, Lags Revenue Estimates - MSN
Revance Therapeutics Reports Q3 Growth Amid Merger Plans - TipRanks
Revance Therapeutics Q3 2024 Earnings: EPS of -$0.37 Beats Estimate, Revenue of $59.9M Misses Expectations - GuruFocus.com
Revance Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Revance Q3 Revenue Up 11% to $59.9M Amid Crown Merger Deal; China Approves DAXXIFY | RVNC Stock News - StockTitan
Top 10 startups in Dermatology in Bay Area, United States in Nov, 2024 - Tracxn
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RVNC, CPTN, RCM on Behalf of Shareholders - Stockhouse Publishing
Revance Therapeutics revises Teoxane agreement, expands distribution to ANZ By Investing.com - Investing.com Canada
Traders Buy High Volume of Put Options on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat
Revance Therapeutics' (RVNC) "Hold" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Revance Therapeutics revises Teoxane agreement, expands distribution to ANZ - Investing.com
Revance Therapeutics (NASDAQ:RVNC) Shares Gap UpHere's What Happened - MarketBeat
Crown Settles Customer Dispute To Close $924M Revance Buy - Law360
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - Benzinga
“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments” - Barchart
Revance Therapeutics surges after Crown tender offer extended, settles with Teoxane - MSN
Revance Shares Rise Premarket on Teoxane Settlement, Tender Extension - MarketWatch
Revance Therapeutics, Inc. and Teoxane SA Enters into the Sixth Amendment to the Exclusive Distribution Agreement - Marketscreener.com
Revance Therapeutics drops as deadline for Crown Lab tender set to expire - MSN
Revance Therapeutics (NASDAQ:RVNC) Shares Down 3.8%Should You Sell? - MarketBeat
Revance Therapeutics extends merger offer date amid Teoxane talks - Investing.com India
Revance Therapeutics extends merger offer date amid Teoxane talks By Investing.com - Investing.com Australia
Revance Therapeutics, Crown Labs Again Extend Tender Offer Deadline - MarketWatch
Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc.RVNC - PR Newswire
The Law Offices of Frank R. Cruz Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors - Business Wire
(RVNC) Trading Signals - Stock Traders Daily
StockNews.com Initiates Coverage on Revance Therapeutics (NASDAQ:RVNC) - MarketBeat
Law Offices of Howard G. Smith Announces Investigation of Revance Therapeutics, Inc. (RVNC) on Behalf of Investors - Marketscreener.com
Revance Therapeutics Inc (RVNC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
3.55%
자본화:
|
볼륨(24시간):